Skip to main content

Contact Precautions May Have Unintended Consequences


Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study.
Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors.
"Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such as fall or pressure ulcer prevention protocols)." The authors also point out that contact precautions have become more common in the past decade thanks to the advent of surveillance programs such as the VA's Methicillin-Resistant Staphylococcus aureus (MRSA) Prevention Initiative.
The researchers conducted the study from April 29, 2010, to December 5, 2011, in 7 intensive-care units (ICUs) and 6 medical-surgical wards at 3 VA hospitals and the University of Maryland Medical Center. Results appear in the January issue of Infection Control and Hospital Epidemiology.
The investigators used a "secret shopper" protocol in which trained researchers observed randomly selected rooms on each unit at least 3 times a week at randomly selected times for a minimum of 1 hour at a time. The observers recorded the entry and exit times of HCWs and other visitors and whether the HCWs complied with contact precautions and hand hygiene on entering and leaving the room.
"Observers maintained their presence as 'secret shoppers' by bringing other reading material and having a prepared story that they were observing human factors related to HCW movement, if asked (which happened rarely after the first few weeks of study)," the authors explain. During the 19-month study period, they observed 7743 HCW visits during 1989 hours of observation.
Patients on contact precautions received 2.78 HCW visits per hour compared with 4.37 visits per hour for patients not on contact precautions ( P < .001). Overall, visit duration was 13.98 minutes per hour for patients on contact precautions compared with 16.98 minutes per hour for conventional patients ( P = .02). However, in a subgroup analysis, the difference was significant among patients on non-ICU, medical/surgical wards (8.59 vs 10.44 minutes/hour; P < .01) but not for ICU patients (16.39 vs 16.70 minutes/hour; P = .51).
In addition, the researchers noted outside visitors on 18.9% of observation periods for patients on contact precautions compared with 24.4% of observation periods for nonisolated patients ( P = .08).
The presence of contact precautions did appear to make HCWs more likely to wash their hands on leaving, but not entering, the patient's room. "HCWs were not significantly more likely to perform hand hygiene on room entry for patients on contact precautions (42.5% [706/1,660]) compared with other patients (30.3% [1,833/6,056]; P = .14)," the authors report. On exiting the room of a patient on contact precautions, however, HCWs maintained hand hygiene 63.2% of the time compared with 47.4% with other patients ( P <.001).
These observations are consistent with the findings of a smaller study conducted some years ago, according to Francesca Torriani, MD, professor of medicine in the Division of Infectious Diseases at the University of California, San Diego, School of Medicine. "The decrease in visits by providers, and in time spent with patients, and decreased visitors is meaningful particularly for non-ICU wards," she said in an email interview with Medscape Medical News.
"In my opinion, this study suggests that contact precautions should be initiated after careful weighing of the positive and negative effects on patient care and safety, as well as emotional well-being. The absence of significant differences in the ICU suggests that with increased acuity the need for provider interaction is recognized and outweighs the barrier to care of contact precautions. However, contact precautions initiated because of a regulatory mandate (such as MRSA Active Surveillance Testing and isolation in California) may be associated with unintended consequences that affect overall safety and quality of care," said Dr. Torriani, who was not involved in this research.
Study limitations include the fact that non-ICU wards were observed only in the VA hospitals, so the findings may not be generalizable to non-VA institutions, and that patient-associated factors such as severity of illness were not taken into account, the authors state.
The effect of limited contact on patient satisfaction also is unclear, Scott McClelland, MD, MPH, associate professor of medicine, epidemiology, and public health at the University of Washington School of Medicine and the university's School of Public Health, told Medscape Medical News in an email interview. The investigators "did not study whether this influenced patient satisfaction and clinical outcomes, and I think it is difficult to be sure about this effect," he said.
Dr. McClelland, who was not involved in this research, also points out that "the overall rates of hand hygiene for both contact precaution patients and those not on contact precautions were disappointingly low. These should be 100% on entry and exit from rooms, regardless of patient type."
Nevertheless, the authors conclude, "Contact precautions were found to be associated with activities likely to reduce transmission of pathogens, such as fewer visits and better hand hygiene, while exposing patients on contact precautions to less HCW contact and potentially more adverse events. Clinicians and healthcare epidemiologists should be aware of the way contact precautions modify care delivery. Researchers need to consider both the positive and negative aspects of interventions using gowns, gloves, and other aspects of patient isolation."
This study was supported by the VA Health Services Research and Development, the Association of American Medical Colleges/Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. Dr. Morgan reports that he has received an unrestricted research grant from Merck. The other authors, Dr. Torriani, and Dr. McClelland have disclosed no relevant financial relationships.

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...